ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,815.03
0.61%
US Tech 100
19,734.40
0.00%
Dow Jones
42,863.86
0.97%
Brent Oil
77.55
0.11%
Bitcoin
64,038.78
1.89%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Inozyme Pharma Inc (INZY) Quote

Inozyme Pharma Inc

Inozyme Pharma Inc (INZY)

NASDAQ
5.18
0.00
(0.00%)
Closed October 14 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
5.18
Bid
5.00
Ask
5.37
Volume
-
0.00 Day's Range 0.00
2.689 52 Week Range 7.795
Market Cap
347.578M
Previous Close
5.18
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
245,724
Shares Outstanding
67,100,000
Dividend Yield
-
PE Ratio
-4.87
Earnings Per Share (EPS)
-1.06
Revenue
-
Net Profit
-71.17M

About Inozyme Pharma Inc

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.inozyme.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INZY. The last closing price for Inozyme Pharma was $5.18. Over the last year, Inozyme Pharma shares have traded in a share price range of $ 2.689 to $ 7.795.

Inozyme Pharma currently has 67,100,000 shares outstanding. The market capitalization of Inozyme Pharma is $347.58 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -4.87.

Ask ADVFN Intelligence (AI)

INZY Latest News

More News

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

October 07 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

October 03 2024
Edgar (US Regulatory)

Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting

- Data underscore the urgent need for therapies that address the cardiovascular and musculoskeletal complications and long-term systemic effects of ENPP1 and ABCC6 Deficiencies in children...

September 26 2024
GlobeNewswire Inc.

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

August 29 2024
GlobeNewswire Inc.

Form 8-K - Current report

August 06 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

August 06 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 06 2024
Edgar (US Regulatory)

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data from ENERGY 1, a Phase 1b trial of...

August 06 2024
GlobeNewswire Inc.

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT - BOSTON, July...

July 25 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1005.185.45524.92015415.12899914CS
4-0.82-13.666666666766.244.91978205.36042756CS
12-0.19-3.538175046555.376.244.212457245.20879599CS
260.071.36986301375.116.244.183237754.84384328CS
521.748.85057471263.487.7952.6894249004.99404932CS
156-4.69-47.51773049659.8710.710.9914400844.37432527CS
260-12.75-71.109871723417.9331.64990.9913318345.32959486CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
$ 11.79
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 64.67
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACGATA Creativity Global
$ 0.9404
(0.00%)
0
AALAmerican Airlines Group Inc
$ 11.79
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 64.67
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACGATA Creativity Global
$ 0.9404
(0.00%)
0
AALAmerican Airlines Group Inc
$ 11.79
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 64.67
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACGATA Creativity Global
$ 0.9404
(0.00%)
0

INZY Discussion

View Posts
Monksdream Monksdream 1 month ago
INZY under $6
👍️0
AJ Freely AJ Freely 1 year ago
$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment
👍️0
Monksdream Monksdream 1 year ago
INZY new 52 week high
👍️0
INFINITI INFINITI 2 years ago
Loading
👍️0
Jess070283 Jess070283 2 years ago
Have a feeling this about to squeeze into a halt soon…..
👍️0
tj9938 tj9938 2 years ago
Great week so far. Gotta keep it movin.
👍️0
tj9938 tj9938 2 years ago
Quietest board out there
👍️0
ErnieBilco ErnieBilco 2 years ago
Grabbed a starter here today
👍️0
crudeoil24 crudeoil24 2 years ago
INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
👍️0
crudeoil24 crudeoil24 2 years ago
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
👍️0
crudeoil24 crudeoil24 2 years ago
Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY
👍️0
tw0122 tw0122 3 years ago
I like the BioXc chart looks better. Thanks for all the good insight.
👍️0
crudeoil24 crudeoil24 3 years ago
The offering is expected to close on or about April 19, 2022
👍️0
tw0122 tw0122 3 years ago
This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 3 years ago
PT > 33.00
👍️0
crudeoil24 crudeoil24 3 years ago
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
👍️0

Your Recent History

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved